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Abstract.  Tenascin/hexabrachion  is a  large glycopro- 
tein of the extracellular  matrix.  Previous reports have 
demonstrated that tenascin is associated with epithe- 
lial-mesenchymal  interfaces during  embryogenesis and 
is prominent in the matrix of many tumors.  However, 
the distribution of tenascin is more restricted in adult 
tissues. 
We have found tenascin to be present in normal hu- 
man skin in a distribution distinct from other matrix 
proteins.  Immunohistochemical  studies showed staining 
of the papillary dermis immediately beneath the basal 
lamina.  Examination  of skin that had been split within 
the lamina lucida of the basement membrane suggested 
a localization of tenascin beneath the lamina lucida.  In 
addition,  there was finely localized staining  within the 
walls of blood vessels and in the smooth muscle bun- 
dles of the arrectori pilorem.  Very prominent  staining 
was seen around the cuboidal cells that formed the 
basal layer of sweat gland ducts.  The sweat glands 
themselves did not stain. 
The distribution of tenascin in the papillary dermis 
was studied at high resolution by immunoelectron mi- 
croscopy. Staining  was concentrated in small amor- 
phous patches scattered amongst the collagen fibers 
beneath the basal lamina.  These patches were not as- 
sociated with cell structures,  collagen,  or elastic 
fibers. 
Tenascin could be partially extracted from the papil- 
lary dermis by urea,  guanidine hydrochloride,  or high 
pH solution.  The extracted protein showed a 320-kD 
subunit similar to that purified from fibroblast or 
glioma cell cultures.  We have developed a  sensitive 
ELISA assay that can quantitate tenascin at concentra- 
tions as low as 5 ng/ml.  Tests on extracts of the papil- 
lary dermis  showed tenascin constituted about 
0.02-0.05 % of the protein extracted. 
T 
~NASCIN/hexabrachion is  a  large  oligomeric glyco- 
protein of the extracellular  matrix.  The name hexabra- 
chion refers to the unique disulfide bonded six-armed 
structure that is the most common form of the glycoprotein 
(15, 16). The protein  has been independently  discovered in 
a number of laboratories and given several names including: 
hexabrachion  (15, 16), myotendinous  antigen (8, 9), GP250 
protein (6, 7), glial mesenchymal extracellular  matrix  pro- 
tein (3, 4), tenascin (2, 10), cytotactin (13, 22), J1 protein (30, 
42), and brachionectin  (17, 47; for review, see reference  16). 
Studies characterizing  this protein indicate tenascin is a col- 
lagenase resistant protein that is distinct from types I, III, IV, 
VI, and VII collagen,  fibrillin,  laminin,  entactin,  fibronec- 
tin,  chondronectin,  and thrombospondin. 
Several laboratories have described the temporal and spa- 
tial localization  of tenascin during embryogenesis.  This dis- 
tribution is much more restricted than  that  of other ECM 
proteins including laminin and fibronectin (1, 2, 8, 10, 13, 17, 
18, 22, 24, 30, 35, 37, 42, 47). Individual  laboratories  have 
focused on different tissues and functional  associations,  in- 
cluding dense connective tissues, developing central nervous 
system, epithelial-mesenchymal interfaces  of embryos, and 
tumor matrix. 
Chiquet and Fambrough  (8) described the localization  of 
tenascin  in a subclass of dense connective tissue including 
perichondrium/periosteum,  ligaments,  and tendons  as well 
as in developing smooth muscle tissues. Vaughan et al., (47) 
also noted the prominence of this protein in cartilage,  from 
which it could be extracted using  high salt.  Mackie et al., 
(35) have reported in vitro studies that suggest tenascin plays 
an active role in the initiation of chondrogenesis.  They pro- 
posed that  tenascin  may act by modulating  the inhibitory 
effects of fibronectin  on chondrocyte differentiation. 
Edelman and colleagues (13, 22) have studied the appear- 
ance of tenascin  in the developing  central  nervous system, 
noting specific temporal  and spatial patterns of expression. 
They proposed that tenascin,  specifically synthesized by glial 
cells, plays a role in neuron-glial interactions (22, 24). Other 
studies  suggest tenascin  plays a role in migration  of neural 
crest cells,  myelination,  and  formation  of neuromuscular 
junctions (12, 40, 42, 44}. 
Tenascin expression during  embryonic morphogenesis is 
also linked to developing epithelial-mesenchymal interfaces. 
Aufderheide  et al., (2) reported on the induction  of tenascin 
in developing kidney only after the differentiation  of an epi- 
thelial  surface from the underlying  mesenchyme.  Similar 
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gut (1). In embryonic skin, several reports have noted promi- 
nent tenascin staining in the mesenchyme beneath develop- 
ing skin appendages, including chicken feather papillae and 
rat hair follicle, tooth bud and mammary gland (8,  10,  13). 
In  contrast to  embryonic tissue,  tenascin expression is 
reportedly very restricted in adult tissues. However, promi- 
nent expression of tenascin in the stroma of several types of 
human tumors was first noted by Bourdon et al., (3, 4). Simi- 
larly, Chiquet-Ehrismann et al.  (10) found the protein ex- 
pressed in developing embryonic rat mammary tissue but 
absent in normal adult tissue. They observed prominent in- 
duction of tenascin in the matrix surrounding chemically in- 
duced mammary carcinomas (10). 
Because of the association of tenascin with dense connec- 
tive tissue, including developing skin, and the matrix sur- 
rounding some epidermally derived tumors, we have exam- 
ined adult skin to determine if tenascin expression persists 
in adult human skin, to determine its ultrastructural localiza- 
tion, and to characterize the protein isolated from skin rela- 
tive to that produced by fibroblast and tumor cells in vitro. 
Materials and Methods 
Antibodies~Antigens 
Monoclonal antibody 81C6, an IgO2b immunoglobulin to human tenascin 
(3, 4), was used for affinity purification of tenascin from culture supernatant 
of a human glioma cell line, U-251  MG clone 3, as previously described 
(18). Tenascin was further purified by gradient sedimentation on a 15-40% 
(vol/vol) glycerol gradient (15, 18) before immunization of rabbits. Antise- 
rum obtained after the second and subsequent boosts was affinity-purified 
on a column prepared by coupling 1 nag of the purified tenascin to cyanogen 
bromide activated sepharose 2-B (45). The affinity-purified antisera had no 
detectable reactivity with collagen types I, III, IV, and V, gelatin, keratin, 
laminin, or fibronectin on ELISA (14) and showed no reactivity to fibrillin, 
collagen types I, III, or VII, laminin, fihronectin, or keratin on Western 
blotting (46).  Antibody from preimmune serum was purified on protein 
A-agarose (Sigma P1406) and used as a negative control in immunolocaliza- 
tion and immunoblotting. A mouse myeloma IgG2b immunoglobulin of no 
known specificity, 45.6 (3, 4), was used as a control for monoclonal studies. 
A mouse monoclonal antibody to fibrillin (41) was the generous gift of 
Dr. L. Sakai  (Oregon Health Sciences University, Portland, OR). Mouse 
monoclonal antibodies to laminin and type VII collagen were provided by 
Dr. R. Briggaman (University of North Carolina, Chapel Hill, NC). Mouse 
monoclonal antibody 3E3 to human fihronectin was from Dr. M. Piersch- 
bacher (La Jolla Cancer Research Foundation, La Jolla, CA). Fluorescein 
and horse radish peroxidase-conjugated goat anti-mouse and anti-rabbit 
were  from Tago  Inc.  (Burlingame,  CA).  Peroxidase avidin-biotinylated 
horseradish peroxidase complex (ABC) 1 kit was from Vector Laboratories, 
Inc. (Burlingame, CA). 
Light Microscopy 
Tissue obtained from surgical specimens of autopsy material was used for 
immunolocalization.  Fresh tissue was embedded in Tissue-Tek  O.  C.  T. 
compound (Miles Scientific, Naperville, IL) and 4-6-/~m sections were cut 
using a microtome (E. Leitz, Rocldeigh, NJ) at -21°C. Sections were fixed 
in cold acetone (-20°C) for 10 min and air dried. Monoclonal antibody 
was used at 6 ~g/ml diluted in 0.25 % gelatin in PBS. Affinity-purified  rabbit 
polyclonal antibody was used at 0.5-1 #g/ml.  Sections were incubated in 
a humidified chamber at room temperature for 30 min. After washing in 
PBS, sections were incubated with fluorescein-conjugated second antibody 
previously adsorbed against human IgG (Tago Inc.) for 30 min at room tem- 
perature. The sections were washed with PBS, covered with 50% glycerol 
in PBS, and visualized (Laborlux 12; E. Leitz). For saline-split skin, tissue 
was incubated for 24 h at 4°C in 1 M NaC1, 10 mM Tris HCI, 0.02 % sodium 
azide, 1 mM EDTA,  1 mM PMSE pH 7.4 (Scaletta buffer), before embed- 
ding and sectioning. Immunolocalization with affinity-purified polyclonal 
anti-tenascin was the same as that seen with 81C6 although, as expected, 
the signal was more intense with the polyclonal antibody. 
Formalin-fixed paraffin-embedded sections were deparaffinized by incu- 
bation overnight in xylene followed by serial rehydration through 100%, 
95 %, and 80% ethanol. After rinsing with water, the sections were blocked 
for 20 min with 10% normal goat serum in PBS. Sections were incubated 
overnight  at  room  temperature  in  a  humidified chamber  with  afffinity- 
purified polyclonal antibody at 1 ~tg/ml in blocking buffer, which gave opti- 
mum specific staining. Preimmune control antibody was used at the same 
concentration. Sections stained with preimmune antibody at 30 ttg/ml gave 
diffuse background but no specific staining. After washing with PBS, the 
bound antibody was visualized by the peroxidase ABC (27) method using 
diaminobenzidine (Sigma Chemical Co., St. Louis, MO) as the developer. 
These sections afforded better preservation of the tissue morphology than 
frozen sections. However, the monoclonal antibody 81C6 was not reactive 
to formalin-fixed sections, so these were stained with the affinity-purified 
polyclonal antibody. Several comparisons of these sections with cryosec- 
tions stained with monoclonal antibodies showed identical localization. 
Electron Microscopic Immunolocalization 
Freshly obtained tissue samples were cut into 2-mm blocks and washed for 
4 h at 4°C with PBS. They were then incubated with affinity-purified anti- 
body or preimmune control antibody at 2.5/zg/ml in 20 mM Tris HCI, 0.1% 
BSA, 0.15 M NaCI, 0.1% sodium azide, pH 8.0 (Tris buffer) at 4°C for 43 h. 
After washing with PBS for 6 h at 4°C, the blocks were incubated with 10- 
nm gold-conjugated goat anti-rabbit antibody (Janssen Life Sciences Prod- 
ucts, Piscataway, NJ) diluted 1:2 with Tris buffer at 4°C for 15 h. The blocks 
were washed for 6 h at 4°C in PBS and fixed in 2.5%  glutaraldehyde in 
0.1 M sodium cacodylate for 3 h. The blocks were extensively washed with 
0.1 M sodium cacodylate, stained for 1 h at 4°C in  1% osmium tetroxide 
in 0.I M sodium cacodylate, washed twice with 0.1 M sodium cacodylate, 
washed twice with 0.9%  NaCI,  and stained with 0.5%  uranyl acetate in 
0.9% NaC1 for 2 h at room temperature. After rinsing with 0.9% NaCI, the 
blocks were dehydrated through 70%, 95%, and 100% ethanol followed by 
propylene oxide. The blocks were embedded in Epon Resin and cut in 60- 
nm sections (Ultracut E, Reichert Scientific Instruments, Buffalo, NY). The 
sections were stained for 30 min in 7.5% uranyl acetate, rinsed with water, 
and counterstained 10 rain with Sato lead stain (43).  Sections were exam- 
ined using an electron microscope (model 300;  Philips Electronic Instru- 
ments, Inc., Mahwah, N J). 
Tissue Extraction 
Tissue  obtained  from autopsy  or  surgical  specimens was  incubated for 
72-96 h at 4°C in Scaletta buffer.  This incubation causes the skin to split 
within the lamina lucida, separating the epidermis from the dermis (21). 
After separation, the basal lamina face of each section was extracted with 
one of several buffers: 0.1 M 3-[cyclohexylamino]-l-propane sulfonic acid 
(CAPS), 0.15 M  NaCl, pH  ll.0; 4  M  urea, 0.1  M sodium borate, 0.5  M 
NaCI, pH 8.4; 4 M guanidine hydrochloride; PBS; or Scaletta buffer at 4°C. 
Frozen sections were prepared following 2 and 7 d of extraction and stained 
for tenascin. The extracts were dialyzed against PBS and total protein was 
estimated by the method of Bradford  (5)  using  reagents from  Bio-Rad 
Laboratories (Richmond, CA). Purified human fibronectin was used as pro- 
tein standard. Tenascin content in the extracts was estimated by ELISA (14, 
see below) using affinity-purified tenascin as a standard. 
ELISA Assay for Tenascin 
96-well plastic plates (Falcon Labware, Becton, Dickinson & Co., Oxnard, 
CA) were coated overnight at 4°C with monoclonal antibody 81C6 at 0.25 
t~g/rnl in sodium carbonate buffer (0.05 M sodium carbonate, 0.02 % sodium 
azide, pH 9.6).  After washing with PBS-Tween (0.05 % vol/vol Tween 20), 
100 #l/well of purified tenascin diluted in 0.25% gelatin in PBS-Tween was 
loaded in a range of 0.25-16 rig/well for a standard curve. All samples were 
assayed in triplicate. Extracts to be tested were diluted in 0.25% gelatin in 
PBS-Tween. Following incubation for 2 h at 37°C,  the plates were washed 
and incubated with affinity-purified rabbit antibody at 0.15/zg/ml in 0.25% 
gelatin in PBS-Tween for 2 h at 37°C. The plates were washed and incubated 
with horse radish peroxidase-conjugated goat anti-rabbit IgG (Tago Inc.) 
at 37°C for 2 h.  Bound antibody was assayed colorimetrically using or- 
thophenylenediamine (Sigma Chemical Co.).  No detectable reactivity of 
affinity-purified antitenascin with mouse antibody was seen. Control plates 
using antibody purified from preimmune serum were also negative. 
The Journal  of Cell Biology,  Volume 108, 1989  2484 Figure L Indirect immunoperoxidase staining of  5-#m sections of formalin-fixed  paraffin-embedded human skin using affinity-purified  poly- 
clonal antibody to human tenascin as described in Materials and Methods. Bound antibody was detected using the ABC peroxidase method. 
Shown are sections stained with preimmune antibody (A) and affinity-purified antibody (B). Prominent staining of the papillary dermis 
(arrow) is seen with enhancement around the infundibulum of the hair follicle (arrowhead). In addition, there is staining of the ductal 
portion of the eccrine sweat gland (open arrows). Bar, 200/zm. 
lmmunoblotting 
Proteins were separated by PAGE by the method of Laemmli (32) on 5% 
gels or 4-15 % gradient gels with 3 % stacking gel. Proteins were transferred 
to nitrocellulose using a  semi-dry blotting apparatus (LKB Instruments, 
Gaithersburg, MD) as described by Kyhse-Andersen  (31). After transfer, the 
nitrocellulose was blocked in 3% BSA in PBS for 1 h at room temperature, 
incubated with monoclonal antibody at 2.5/~g/m! or affinity-purified poly- 
clonai antibody at 0.5 #g/ml in 1% BSA in PBS-Tween for 2 h at room tem- 
perature, and washed with PBS-Tween. After incubation with horse radish 
peroxidase-conjugated antisera for 2  h  at room temperature and washing 
with PBS-Tween, bound antibody was visualized using 4-chloronaphthol 
(Bio-Rad Laboratories) or diaminobenzidine (Sigma Chemical Co.). 
Results 
Distribution of Tenascin in Normal Adult Skin 
Adult human skin from normal and pathological specimens 
was examined for presence of tenascin using immunofluores- 
cent and peroxidase techniques. In normal adult skin, tenas- 
cin is localized primarily in the papillary dermis (Figs. 1 and 
2). The staining was more pronounced within the papillary 
tips and was frequently sparse at the base of the rete ridges. 
The coarse patchy staining seen (Figs. 1 B, and 2 A) was dis- 
tinct  from the  fine fibrillar pattern  seen with  antifibrillin 
staining (Fig. 2 B), and the more punctate staining seen with 
antifibronectin (Fig. 2 C). In contrast to staining seen with 
antibodies to the basal lamina (type IV collagen and laminin) 
or with antibodies to the immediate sublamina space (type 
VII collagen, Fig.  2  D),  the band of tenascin staining ex- 
tended  2-10-/zm  into  the  dermis.  Skin  was  incubated  in 
Scaletta buffer to induce splitting within the lamina lucida 
(21). Immunostaining of saline split skin showed tenascin in 
the separated dermis, but no staining of the epidermal layer 
above the lamina lucida (Fig.  3). 
In addition, antibodies to tenascin gave pronounced stip- 
pled staining of arrector pilorum (Fig. 4 A) and nerves as 
well as some staining of arteries (Fig. 4 B), capillaries, and 
veins.  In  arteries,  the  staining  appears  to  be  within  the 
smooth muscle of the arterial wall and  not limited to the 
basement membrane (Fig. 4 B). 
There is striking staining of the eccrine sweat ducts but no 
staining of the sweat glands (Fig. 4  C). The sweat ducts ex- 
tending towards the epidermis stained intensely for tenascin. 
The coiled portion of the gland,  which is primarily sweat 
gland but can include up to one third duct, showed no stain- 
ing in many of the deeper coils. However, there was intense 
staining of up to one third of the tubules in more superficial 
coils (Fig. 1). This pattern suggests that the tenascin staining 
is limited to the ductal portion of sweat glands. The eccrine 
sweat duct is lined by two layers of cuboidal epithelial cells: 
an outer cell layer that rests on a basement membrane and 
an inner cell layer that has a cuticular border. The tenascin 
staining appears to completely surround the duct and extend 
between the outer cell layer to the inner cell layer, but does 
Lightner et al.  Tenascin/Hexabrachion  in Human  Skin  2485 Figure 3. Indirect immunofluorescent staining of 5-#m frozen section of saline split human skin using affinity-purified  polyclonal antibody 
to tenascin. Human skin was incubated for 24-h in Scaletta buffer before embedding to induce splitting within the lamina lucida of the 
basement membrane as described in Materials and Methods. (A) phase contrast, (B) immunofluorescent staining. Roof of the split (epider- 
mis) (open arrows), and base of the split (dermis) (solid arrows). Bar,  10 #m. 
not appear to extend to the lumen (Fig. 4  C).  The staining 
is lost when the ducts enter the epidermis (Fig. 4 D). 
Pretreatment of sections  with  elastase,  collagenase,  or 
hyaluronidase did not eliminate  nor enhance the tenascin 
staining observed (not shown). Incubation of sections with 
PBS, Scaletta buffer, 4 M urea, or CAPS buffers was also un- 
able to remove tenascin staining,  although there was some 
decrease  in  the  sections  treated  with  the  latter  two  (not 
shown). Incubation of sections with guanidine hydrochloride 
removed the sections from the slide. 
In contrast to normal adult skin, dermis that was involved 
with primary  malignancy (dermatofibrosarcoma protuber- 
ans, Fig. 5 A) or secondary invasion (squamous cell carci- 
noma,  Fig.  5  B)  showed marked  increase in the tenascin 
staining in the matrix of the tumor. However, the nests of in- 
vasive squamous cells did not stain.  This is in agreement 
with observations reported by Bourdon et al., (3) as well as 
Chiquet-Ehrismann  et al.,  (10)  on the distribution of this 
protein in tumors.  In addition, examination of granulation 
tissue in rat skin in the late stages of  healing after third degree 
burn (sections provided by Dr. A. Banes, University of North 
Carolina,  NC)  revealed  markedly  enhanced  staining  for 
tenascin (Fig. 5 C). The tenascin was prominent throughout 
the granulation tissue as well as laterally beneath the wound 
edge.  The time course of induction of tenascin in  wound 
healing is currently under study in our laboratories. 
Electron Microscopic Immunolocalization 
Studies on human skin demonstrated tenascin was present in 
small amorphous patches within the papillary dermis (Fig. 
6). These patches were not labeled in control blocks stained 
with preimmune antibody. However, in the absence of label- 
ing, the patches are indistinguishable from the many micro- 
fibrillar components and other amorphous patches in the der- 
mis. No labeling was seen in the basement membrane or in 
the zone immediately beneath the lamina densa where char- 
acteristic anchoring fibrils are seen.  The tenascin patches 
were not specifically associated with collagen or elastic fibers 
or cell surfaces. The labeled patches were often smaller in 
size than a  well-spread hexabrachion molecule (see rotary 
shadowed molecule in inset, Fig. 6). Examination of multi- 
ple  sections from several blocks failed to reveal any long 
strands of labeling, although a few extended patches of label 
were seen (Fig. 6 B). It thus appears unlikely that tenascin 
associates in an extended fiber like collagen or elastic mi- 
crofibrils. These findings suggest the smaller patches may 
represent single or small clusters of  hexabrachion molecules. 
Enbloc staining with monoclonal antibody to tenascin gave 
essentially the same distribution as the affinity purified poly- 
clonal antibody but with less intense gold labeling (not shown). 
Extraction of Tenascin from Normal Skin 
Extraction of tenascin from the dermal-epidermal junction 
of saline split skin was attempted using five buffers: (a) PBS; 
(b)  1 M  NaCI,  10 mM Tris HCI,  1 mM EDTA, 0.02 % so- 
dium azide, pH 7.4 (Scaletta buffer); (c) 0.1 M CAPS, 0.15 M 
NaCI, pH  11; (d) 4  M  urea in borate buffer; and (e) 4  M 
guanidine hydrochloride. In spite of prolonged incubation, 
no buffer completely removed the tenascin as assessed by im- 
munohistochemistry. The staining observed after CAPS ex- 
traction  was  reduced  ~50%  and  was  more diffuse when 
compared to the other extraction buffers. Because of this, the 
CAPS extracts were chosen for further analysis. 
The CAPS extracts were examined for tenascin by Western 
blotting using affinity-purified polyclonal antibodies and the 
monoclonal antibody 81C6. As shown in Fig. 7 A, the extract 
Figure 2. Indirect immunofluorescent staining of 5-tim frozen sections of normal human skin using monoclonal antibodies to (A) tenascin, 
(B) fibrillin, (C) fibronectin, and (D) type VII collagen. DEJ (long arrows), and the outer border of the epidermis (short arrows). Bar, 
10 t~m. 
Lightner et al. Tenascin/Hexabrachion in Human Skin  2487 Figure 4. Indirect immunoperoxidase staining of  5-#m sections of  formalin-fixed paraffin-embedded human skin using affinity-purified poly- 
clonal antibody to tenascin.  (A) Intense staining of the papillary dermis (arrowhead) as well as a network staining of an arrector pilorum 
muscle (arrow). (B) Staining within the wall of an artery in the hypodermis (arrow). (C) Intense staining of the ductal portion of an eccrine 
sweat gland (arrow) with no staining of the adjacent gland (arrowhead). The staining appears to extend between the ceils of the outer cuboi- 
dal cell layer. (D) Staining of the sweat duct (arrow) is lost upon entering the epidermis (arrowhead).  Bars, (A), (B), (D) 100 tim; (C) 
20 #m. 
of the dermal face of the dermal-epidermal junction  con- 
rained a 320-kD band that was recognized by both the poly- 
clonal  (lane  3)  and  monoclonal  (lane  4)  antibodies.  This 
band had the same electrophoretic mobility as the tenascin 
purified from the glioblastoma cell line (lane/).  The mass 
of 320-kD was estimated relative to a set of very high molec- 
ular mass standards (Fig. 7 B and C) including reduced lami- 
nin,  nonreduced  fibronectin,  reduced  fibronectin,  and  re- 
duced pig thyroglobulin.  As noted in Fig.  7  C,  these very 
high molecular mass standards deviate significantly from the 
curve estimated using high molecular mass markers (Bio- 
Rad Laboratories; Fig. 7 B, lane 3). This new curve is more 
accurate for estimating the size of similarly very large pro- 
teins, including the tenascin monomer (Fig. 7 B, lane 4 on 
gel, and C, arrow). Additional bands at ,,0640  kD (arrow) 
and at the top of the gel are noted in Fig. 7 A, lane 3.  The 
'~640  kD  band  is  thought  to  represent  covalently  linked 
dimers of tenascin (17).  The band at the top of the gel rep- 
resents complexes larger than 820 kD (the size of unreduced 
laminin). Whether these are trimers or complexes oftenascin 
with other molecules is not known. Both bands also blotted 
faintly with monoclonal antibodies to tenascin.  The •640- 
kD  band is  also  seen in  silver stained  SDS-PAGE gels of 
tenascin affinity-purified using 81C6  (Fig.  7  B,  lane 4,  ar- 
row).  The additional  faint bands in  Fig.  7  A,  lane 3,  may 
reflect breakdown products in the extract or minor alterna- 
tively spliced forms oftenascin. They are recognized by both 
the affinity-purified polyclonal antibody and the monoclonal 
antibodies to tenascin but are uniformly more intense with 
the  polyclonal  antibody.  No  tenascin  was  detected  in  the 
epidermal extracts stained with 81C6  (not shown).  A  very 
faint amount of staining was seen with the polyclonal anti- 
body (Fig. 7 A, lane 2). This probably represents trace con- 
tamination with dermis during the mechanical separation of 
epidermis from dermis as neither light nor electron micro- 
scopic localization show any tenascin above the lamina lu- 
cida. However, we cannot rule out very low levels of tenascin 
in the epidermis. 
The  tenascin  content  of these  extracts  was  determined 
using an ELISA assay. As shown in Table I, no detectable 
The Journal of Cell Biology, Volume  108,  1989  2488 Figure 5. Indirect immunoperoxidase staining of 5-#m sections of tumor matrix and granulation tissue in skin. (A) Dermatofibrosarcoma 
protuberans  stained with affinity-purified antibody to tenascin.  There is intense staining of the area involved with tumor (arrow) as well 
as the thin band of staining normally seen in the papillary dermis. (B) Invasive squamous cell carcinoma stained with monoclonal antibody 
81C6 to tenascin.  Note the prominent staining of the matrix surrounding the tumor islands (arrowhead) but no staining of the carcinoma 
cells (arrow). (C) Rat granulation tissue, 30 d after third degree burn,  stained with affinity-purified antibody to tenascin.  There is intense 
diffuse staining of the granulation tissue (solid arrows) that extends beneath the wound edge (open arrow). This is in marked contrast to 
the normal dermis at the right edge of the specimen that shows staining restricted to hair follicles (small arrowheads) and the DEJ (large 
arrowhead). Bars,  (A and B) 200/~m;  (C) 400 t~m. 
tenascin was extracted from the epidermal face of the der- 
mal-epidermal  junction (DEJ). While detectable amounts of 
tenascin were found in the extracts of the dermal face of the 
DEJ, these represented a small percentage of the total protein 
extracted (average 0.026%).  However, because only part of 
the tenascin could be extracted from the dermis, we cannot 
quantitate  the  total tenascin  found  in  skin.  Whole dermis 
homogenates had less tenascin than extracts of the DEJ,  in 
agreement with the histological studies which localized the 
protein to the zone adjacent to the DEJ. In contrast,  an ex- 
tract of a dermal tumor had significantly higher amounts of 
extractable tenascin than the whole skin or the DEJ extracts. 
Discussion 
The extracellular matrix proteins in the dermis of skin form 
the  foundation necessary for maintenance of the  structure 
and function of  the skin. We have demonstrated that tenascin, 
a newly described 320-kD glycoprotein, is a structural com- 
ponent of normal adult dermis with a  highly  specific and 
unique distribution.  Previous studies by Bourdon et al.  (3) 
and Chiquet-Ehrismann et al.  (10)  failed to detect tenascin 
in adult mammalian skin, although studies by Crossin et al. 
(13)  showed tenascin persisted at the dermal-epidermal in- 
terface in adult chicken skin. The failure of human skin ex- 
Lightner et al.  Tenascin/Hexabrachion  in Human  Skin  2489 Figure 6. Electron microscopic immunolocalization  of tenascin in the dermis of adult human skin. (A) Beneath the DKI, small amorphous 
patches are labeled with 10-nm gold.  These patches are not specifically associated  with collagen (solid arrows) or elastic  fibers (open 
arrow). No labeling of the basement membrane or immediate sublamina zone is seen (lamina densa,/arge arrowhead; anchoring fibril, 
small arrowhead). Insert shows a rotary shadowed hexabrachion molecule  at the same magnification.  (B), (C), (D) Deeper in the papillary 
dermis there are fewer patches,  but they still show no obvious association with the collagen fibers (solid arrows). Bar, 0.2 #m. 
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CAPS extracts of the epidermal and der- 
mal  faces of saline  split  skin.  Human 
skin was incubated in Scaletta buffer to 
separate the epidermis  from the dermis 
within the lamina lucida as described in 
Materials and Methods. The basal lam- 
ina face was extracted with CAPS buffer 
and run on 5% SDS-PAGE before West- 
ern  blotting.  Lane  1  was  loaded  with 
purified tenascin from cultured glioblas- 
toma cell line U-251 MG, lane 2 with the 
extract  of the  epidermal  aspect  of the 
DEJ, and lanes 3 and 4 were loaded with 
the extract of the dermal aspect of the 
DEJ. Lanes 1, 2, and 3 were blotted with 
affinity-purified  polyclonal  antibody. 
Lane 4 was blotted with the monoclonal 
antibody  81C6. (B)  Silver-stained  5% 
SDS-PAGE on  tenascin  for molecular 
mass  determination.  Lane  1,  reduced 
Engelbreth-Holm-Swarm tumor laminin 
(400 kD; 215 and 205 kD not individu- 
ally resolved); lane 2, reduced human plasma fibronectin (250 kD); lane 3, Bio-Rad high molecular mass marker (200, 116.25, and 97.4 
kD); lane 4, reduced tenascin that had been afffinity-purified  using monoclonal antibody 81C6; lane 5, nonreduced human plasma fibronectin 
(500 kD); and lane 6, nonreduced tenascin (does not enter main gel, band in stacker). The relative mobilities of these proteins were used 
to generate the graph in C for estimating the size of the tenascin monomer. (C) The relative mobility of tenascin (arrow). The gel estimates 
for tenascin range from 320 to 340 kD on this type of curve, which correlates  with its comigration with reduced pig thyroglobulin (330 
kD, not shown). 
tracts to immunoadsorb the monoclonal antibody 81C6  (3) 
was most likely because of the low tenascin content of skin 
relative to other tissues.  In contrast to previous reports by 
Chiquet-Ehrismann  et al.  (10),  we  have found  staining  of 
adult rat skin very prominently around the hair follicles as 
well as less intensely along the DEJ. This discrepancy may 
reflect the lower level of staining of normal skin relative to 
that of the tumor matrix examined by Chiquet-Ehrismann et 
al., (10) as well as a poorer cross-reactivity of the rat tenascin 
with the antibody to chicken tenascin. 
The function of tenascin in skin is not known. The promi- 
nence of this protein near the basal lamina in light micro- 
scopic  studies  suggests  a  possible  role  in  maintenance  of 
the DEJ.  However, immunoelectron microscopy shows that 
tenascin is not an integral component of the basal lamina and 
lies beneath the anchoring fibrils. In addition,  the tenascin 
staining reveals only discrete small patches and no evidence 
of organization into long fibers or fibrils. A complex network 
of tenascin that might play a  structural  role in maintaining 
the  integrity of the subbasal lamina space cannot be ruled 
out.  The  inability  to extract tenascin  completely from the 
dermis might suggest some fraction of the hexabrachion mol- 
ecules  are  cross-linked,  possibly to  other  dermal  compo- 
nents. 
The pattern of tenascin staining does not reveal any obvi- 
ous association with collagen fibers or elastic microfibrils to 
suggest a  role in cross-linking these structures.  A  previous 
report on J1 protein had suggested tenascin staining of large 
collagen  fibers as  well as  small collagen-associated fibers 
(42). Similar results were reported recently by Mackie et al. 
(35) for tenascin.  However, these studies utilized a peroxi- 
dase reaction product to immunolocalize the tenascin.  This 
product can diffuse small distances from the site of produc- 
tion and be adsorbed nonspecifically by adjacent structures 
(38) so is not as specific as immunogold for electron micro- 
scopic localization. In our study, we found no immunogold 
labeling of collagen fibers or elastic microfibrils. 
Recently, Fine et al. (19, 20, 25, 26) have reported on two 
new proteoglycan epitopes in the upper papillary dermis of 
skin,  similar to  what we have seen with tenascin.  One of 
these epitopes is a heparan sulfate proteoglycan core protein 
(25, 26) and the second a complex proteoglycan bearing both 
heparan  sulfate  and  chondroitin-6  sulfate  side  chains  (19, 
20).  Several studies have suggested tenascin binds to chon- 
droitin sulfate proteoglycans (9,  23,  47).  It is possible that 
the tenascin in dermis is interacting with the proteoglycan 
matrix that  is not  stained  in  these immunoelectron micro- 
Table I. ELISA Assay on CAPS Extracts of Skin 
Percent  of total 
Total protein  Tenascin  protein that 
Extract  mg/ml  #g/ml  is tenascin 
E 1  0.603  <0.02  <0.003 
DI  0.921  0.440  0.048 
E2  0.53  <0.02  <0.004 
D2  2.04  0.177  0.009 
E3  0.584  <0.02  <0.003 
D3  i.55  0.313  0.02 
skin  16.6  <0.065  <0.0004 
DFSP  26.5  17.20  0.065 
Three separate skin samples were split at the DEJ,  and the dermal and epider- 
mal faces were extracted as described in Materials and Methods.  In addition, 
homogenates  of a  sample of whole skin as  well as a  sample of a  derma- 
tofibrosarcoma  protuberans  were made in the same buffer.  The extracts were 
analyzed for tenascin content  and total protein as described in Materials and 
Methods.  El, 2, and 3 represent extracts of the epidermal face of the DEJ.  D 1, 
2,  and  3 represent extracts of the dermal face of the DEJ. 
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bodies to the proteoglycan matrix and antitenascin  antibodies 
should help define if there is colocalization of these antigens. 
The tenascin staining  of the ductal  portion of the sweat 
glands suggests a tighter association with the basement mem- 
brane of these structures than with the DEJ. Because of poor 
preservation of these structures in the en bloc stained immu- 
noelectron microscopy sections, we have not yet been able 
to visualize the precise localization of the tenascin in these 
ducts.  At the light microscope level, the striking  staining  of 
the  ductal  portion of sweat glands  but virtual  absence  of 
staining  of the glandular  or intraepidermal  portions of the 
gland  suggests  a  significant  role for tenascin  in the  sweat 
ducts. 
Several  recent studies suggest tenascin may play  a more 
significant role in the maintenance of epidermal histogenesis 
than as a structural component. E.  Mackie et al.  (35) have 
shown tenascin can promote chondrogenic and osteogenic 
differentiation in vivo and chondrogenesis in vitro in wing 
bud cultures from chick embryos. This differentiation  is nor- 
mally  inhibited by  fibronectin,  suggesting  tenascin modu- 
lates the effects of this protein. Other workers have also sug- 
gested  a  role  for  tenascin  in  modulating  ceU-fibronectin 
interactions  (11). While some studies on purified tenascin 
have suggested tenascin binding to fibronectin (11, 23, 24), 
other laboratories  find no evidence of direct tenascin-fibro- 
nectin binding (9, 34).  Even though  tenascin does not com- 
pletely colocalize with fibronectin in skin, it is interesting  to 
speculate that the presence of both of these proteins in the 
papillary dermis adjacent  to the  basal  lamina is not coin- 
cidental. 
Bourdon et al.  (3) first noted the prominence of tenascin 
in the matrix of several  carcinomas but absence of tenascin 
production by established carcinoma cell lines in culture. We 
have also observed prominent staining  of the matrix of sev- 
eral carcinomas of epidermal origin (Fig. 6, and our manu- 
script in preparation).  These observations,  along  with the 
unique  localization  of tenascin  in normal dermis,  suggest 
that fibroblast  production of tenascin may be regulated  by 
factors produced by the epidermis or carcinoma (16), a view 
also proposed recently by Inaguma  et al. (28) in their work 
on rodent mammary tumors, Aufderheide et al. (1 and 2) in 
developing  embryos,  and  Mackie  et  al.  (36)  in  healing 
wounds. 
Recently, studies reported by Jones et al. (29) and Pearson 
et al. (39) have shown tenascin contains a string of 13 repeats 
homologous to epidermal growth factor  (EGF).  These re- 
peats have a high homology with the EGF-like repeats of the 
notch protein of Drosophila that may play a role in promoting 
differentiation of ectodermal cells into epidermal structures 
(48). It is also of note that many human glioblastomas, which 
show high levels of expression of tenascin (3), frequently ex- 
hibit amplification of the EGF receptor gene as well as a high 
degree of expression of the receptor (33, 49). The interaction 
of tenascin with these receptors and the effects of tenascin on 
keratinocyte  growth and differentiation  are currently  under 
investigation  in our laboratory. 
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